Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lung Diseases × zipalertinib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Lung Neoplasms 1 Lung Diseases 1

Interventions

Carboplatin 5 pembrolizumab 3 Pemetrexed 3 Cisplatin 3 Paclitaxel 2 zipalertinib 1 zimberelimab 1 sacituzumab govitecan 1 pralsetinib 1 patritumab 1 camrelizumab 1 alectinib 1 Thrombin 1 Talc 1 TachoSil 1 TNFSF10 protein, human 1 Surveys and Questionnaires 1 Nivolumab 1 Injections 1 Gemcitabine 1 Fibrinogen 1 Erlotinib Hydrochloride 1 Docetaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973773 2026-03-10

REZILIENT3

Taiho Oncology, Inc.

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡